ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 130 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185 | -33.5% | 27,043 | +0.9% | 0.00% | – |
| Q2 2023 | $278 | +28.1% | 26,811 | -0.2% | 0.00% | – |
| Q1 2023 | $217 | -70.5% | 26,858 | -42.5% | 0.00% | -100.0% |
| Q4 2022 | $736 | -99.9% | 46,739 | -0.1% | 0.00% | 0.0% |
| Q3 2022 | $737,000 | +36.0% | 46,808 | +20.5% | 0.00% | 0.0% |
| Q2 2022 | $542,000 | -19.3% | 38,855 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $672,000 | +47.7% | 38,955 | +24.3% | 0.00% | – |
| Q4 2021 | $455,000 | -19.3% | 31,327 | -0.1% | 0.00% | -100.0% |
| Q3 2021 | $564,000 | -13.6% | 31,347 | -15.7% | 0.00% | 0.0% |
| Q2 2021 | $653,000 | +2006.5% | 37,200 | +25.5% | 0.00% | – |
| Q1 2020 | $31,000 | -44.6% | 29,649 | 0.0% | 0.00% | – |
| Q4 2019 | $56,000 | +75.0% | 29,649 | 0.0% | 0.00% | – |
| Q3 2019 | $32,000 | -50.8% | 29,649 | 0.0% | 0.00% | – |
| Q2 2019 | $65,000 | -63.5% | 29,649 | 0.0% | 0.00% | – |
| Q1 2019 | $178,000 | -18.7% | 29,649 | 0.0% | 0.00% | – |
| Q4 2018 | $219,000 | -49.2% | 29,649 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $431,000 | -27.2% | 29,649 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $592,000 | +42.3% | 29,649 | +24.8% | 0.00% | 0.0% |
| Q1 2018 | $416,000 | -29.0% | 23,749 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $586,000 | +5.4% | 23,749 | +10.2% | 0.00% | 0.0% |
| Q3 2017 | $556,000 | -13.4% | 21,549 | -8.9% | 0.00% | 0.0% |
| Q2 2017 | $642,000 | +68.5% | 23,661 | +85.1% | 0.00% | 0.0% |
| Q1 2017 | $381,000 | -10.4% | 12,784 | -18.3% | 0.00% | 0.0% |
| Q4 2016 | $425,000 | +16.8% | 15,646 | +10.1% | 0.00% | 0.0% |
| Q3 2016 | $364,000 | +73.3% | 14,212 | +25.2% | 0.00% | – |
| Q2 2016 | $210,000 | +356.5% | 11,349 | +363.4% | 0.00% | – |
| Q1 2016 | $46,000 | – | 2,449 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |